Analyzing and Modeling the Spread of SARS-CoV-2 Omicron Lineages BA.1 and BA.2, France, September 2021-February 2022.
BA.1
BA.2
COVID-19
France
Omicron
PCR
SARS-CoV-2
coronavirus disease
epidemiology
genomics
mass screening
mutation
respiratory infections
severe acute respiratory syndrome coronavirus 2
vaccine-preventable diseases
variants
viruses
zoonoses
Journal
Emerging infectious diseases
ISSN: 1080-6059
Titre abrégé: Emerg Infect Dis
Pays: United States
ID NLM: 9508155
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
pubmed:
2
6
2022
medline:
22
6
2022
entrez:
1
6
2022
Statut:
ppublish
Résumé
We analyzed 324,734 SARS-CoV-2 variant screening tests from France enriched with 16,973 whole-genome sequences sampled during September 1, 2021-February 28, 2022. Results showed the estimated growth advantage of the Omicron variant over the Delta variant to be 105% (95% CI 96%-114%) and that of the BA.2 lineage over the BA.1 lineage to be 49% (95% CI 44%-52%). Quantitative PCR cycle threshold values were consistent with an increased ability of Omicron to generate breakthrough infections. Epidemiologic modeling shows that, in spite of its decreased virulence, the Omicron variant can generate important critical COVID-19 activity in hospitals in France. The magnitude of the BA.2 wave in hospitals depends on the level of relaxing of control measures but remains lower than that of BA.1 in median scenarios.
Identifiants
pubmed: 35642476
doi: 10.3201/eid2807.220033
pmc: PMC9239895
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1355-1365Références
Biol Lett. 2011 Apr 23;7(2):210-3
pubmed: 20810425
Epidemics. 2021 Jun;35:100459
pubmed: 34015676
Nature. 2022 Mar;603(7902):679-686
pubmed: 35042229
Lancet. 2022 Jan 29;399(10323):437-446
pubmed: 35065011
Science. 2020 Jul 10;369(6500):208-211
pubmed: 32404476
Nat Med. 2022 Apr 8;:
pubmed: 35395151
Nature. 2022 Mar;603(7902):700-705
pubmed: 35104835
Anaesth Crit Care Pain Med. 2021 Aug;40(4):100943
pubmed: 34479681
Nature. 2022 Mar;603(7902):715-720
pubmed: 35104836
Nature. 2021 May;593(7858):266-269
pubmed: 33767447
Am J Epidemiol. 2013 Nov 1;178(9):1505-12
pubmed: 24043437
Euro Surveill. 2021 Jul;26(28):
pubmed: 34269174
N Engl J Med. 2022 Mar 10;386(10):995-998
pubmed: 35081300
Nature. 2022 Feb;602(7898):671-675
pubmed: 35016199
Nature. 2022 Mar;603(7902):706-714
pubmed: 35104837
Euro Surveill. 2021 Sep;26(37):
pubmed: 34533119
Euro Surveill. 2021 Dec;26(50):
pubmed: 34915977
Euro Surveill. 2022 Feb;27(6):
pubmed: 35144725
JAMA. 2022 Feb 8;327(6):583-584
pubmed: 34967859
Trends Microbiol. 2021 Nov;29(11):970-972
pubmed: 34535373
Science. 2021 Apr 9;372(6538):
pubmed: 33658326
Int J Infect Dis. 2020 Apr;93:284-286
pubmed: 32145466
Lancet. 2021 Apr 17;397(10283):1459-1469
pubmed: 33844963
J Med Virol. 2022 May;94(5):2265-2268
pubmed: 34967453
Euro Surveill. 2022 Feb;27(6):
pubmed: 35144722
Emerg Infect Dis. 2021 May;27(5):1496-1499
pubmed: 33769253
Science. 2021 Jul 16;373(6552):
pubmed: 34083451
Lancet. 2022 Apr 2;399(10332):1303-1312
pubmed: 35305296